Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.71 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.71 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.71 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.71 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2154121 | 0.91 | MTOR (1.00) | MTOR | |
| SCHEMBL13828809 | 0.90 | MTOR (0.81) | MTORPIK3CAPIK3CDPIK3C2BPIK3CB | |
| SCHEMBL2153911 | 0.88 | MTOR (1.00) | MTORPIK3CAPIK3CG | |
| SCHEMBL13718781 | 0.86 | MTOR (0.90) | MTOR | |
| SCHEMBL2153364 | 0.84 | MTOR (0.80) | MTOR | |
| SCHEMBL13718892 | 0.84 | MTOR (0.84) | MTOR | |
| SCHEMBL2153938 | 0.84 | MTOR (0.91) | MTOR | |
| Gedatolisib SCHEMBL32393 | 0.83 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3C2BPIK3CB | |
| Gedatolisib SCHEMBL20765097 | 0.83 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3C2BPIK3CB | |
| SCHEMBL2154105 | 0.83 | MTOR (1.00) | MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9801888-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2017-10-31 | — | — | US | claimed |
| EP-2519102-B1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DEV CENTER BIOTECHNOLOGY (TW) | 2016-10-19 | — | — | EP | claimed |
| US-20160136176-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-05-19 | — | — | US | claimed |
| US-9315491-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-04-19 | — | — | US | claimed |
| US-20140178360-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2014-06-26 | — | — | US | claimed |
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2012-11-15 | — | — | US | claimed |
| US-9801888-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2017-10-31 | — | — | US | disclosed |
| US-9801888-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2017-10-31 | — | — | US | disclosed |
| EP-2519102-B1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DEV CENTER BIOTECHNOLOGY (TW) | 2016-10-19 | — | — | EP | disclosed |
| EP-2519102-B1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DEV CENTER BIOTECHNOLOGY (TW) | 2016-10-19 | — | — | EP | disclosed |
| US-20160136176-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-05-19 | — | — | US | disclosed |
| US-20160136176-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-05-19 | — | — | US | disclosed |
| US-9315491-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-04-19 | — | — | US | disclosed |
| US-9315491-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-04-19 | — | — | US | disclosed |
| US-20140178360-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140178360-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2012-11-15 | — | — | US | disclosed |
| EP-2519102-A2 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | Development Center For Biotechnology (TW) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011080568-A2 | NOVEL PYRIMIDINE COMPOUNDS AS MTOR AND P13K INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | MTOR 1/4885PIK3CA 2/4885PIK3CD 5/4885 |
| US-20160136176-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | MTOR 1/4885PIK3CA 2/4885PIK3CD 5/4885 |
| US-20140178360-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | MTOR 1/4885PIK3CA 2/4885PIK3CD 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.